Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise

What happened

Sanofi reported third-quarter 2026 adjusted earnings of $2.04 per American depositary share, beating the Zacks Consensus Estimate of $1.63. Revenue was $16.62 billion, above the $15.23 billion estimate. Net sales rose 16.2% on a reported basis, driven by Dupixent and new medicines.

Confirmed

Global impact / market context

Stronger-than-expected profit and sales suggest Sanofi's key drug Dupixent and recently acquired medicines are selling well. That supports cash coming in and could fund future research or deals. Beating estimates can also make investors more willing to hold the stock, though results reflect past quarters, not guaranteed future gains.

Analyst inference

Sanofi shares rose after the beat, showing investors rewarded the results. Dupixent, sold with Regeneron, is the main growth engine, so its 34.8% sales increase matters most. Sales gains from favorable price adjustments and patient switches suggest demand is broadening, but currency swings and drug pricing pressure remain risks for drugmakers.

Analyst inference

What to watch

1. Watch whether Dupixent sales keep growing at a similar pace, since the article says it drove growth and rose 34.8% to €5.69 billion, with U.S. sales up 40.2%. Confirmed
2. Watch how much Sanofi invests in research and new medicine deals, because strong cash from these sales could fund capital spending or acquisitions that shape future revenue. Proposed
3. Watch currency effects and gross-to-net price adjustments, which the article links to U.S. Dupixent sales; changes there could help or hurt reported sales even if patient demand holds steady. Analyst inference

Evidence

• zacks.com